Carnegie Investment Counsel Acquires 61,560 Shares of Hims & Hers Health, Inc. $HIMS

Carnegie Investment Counsel lifted its holdings in Hims & Hers Health, Inc. (NYSE:HIMS) by 25.4% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 303,909 shares of the company’s stock after acquiring an additional 61,560 shares during the period. Carnegie Investment Counsel owned 0.13% of Hims & Hers Health worth $17,238,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in HIMS. HighTower Advisors LLC bought a new position in Hims & Hers Health in the 1st quarter worth approximately $482,000. American Century Companies Inc. boosted its position in shares of Hims & Hers Health by 31.5% during the first quarter. American Century Companies Inc. now owns 185,065 shares of the company’s stock worth $5,469,000 after acquiring an additional 44,307 shares during the last quarter. Smartleaf Asset Management LLC grew its stake in Hims & Hers Health by 15.7% during the first quarter. Smartleaf Asset Management LLC now owns 1,672 shares of the company’s stock valued at $49,000 after acquiring an additional 227 shares in the last quarter. Ieq Capital LLC increased its holdings in Hims & Hers Health by 39.4% in the 1st quarter. Ieq Capital LLC now owns 57,361 shares of the company’s stock valued at $1,695,000 after acquiring an additional 16,224 shares during the last quarter. Finally, OMERS ADMINISTRATION Corp purchased a new stake in Hims & Hers Health in the 1st quarter worth $1,421,000. Institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Stock Performance

Shares of NYSE:HIMS opened at $34.33 on Friday. The firm’s 50 day simple moving average is $39.70 and its 200-day simple moving average is $47.83. The company has a debt-to-equity ratio of 1.67, a quick ratio of 1.64 and a current ratio of 1.88. Hims & Hers Health, Inc. has a one year low of $23.97 and a one year high of $72.98. The firm has a market cap of $7.81 billion, a PE ratio of 63.57, a price-to-earnings-growth ratio of 6.86 and a beta of 2.41.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings data on Monday, November 3rd. The company reported $0.06 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by ($0.03). The firm had revenue of $598.98 million during the quarter, compared to the consensus estimate of $578.99 million. Hims & Hers Health had a return on equity of 24.67% and a net margin of 6.05%.The firm’s revenue for the quarter was up 49.2% compared to the same quarter last year. During the same period last year, the company earned $0.32 EPS. As a group, equities analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Hims & Hers Health announced that its Board of Directors has initiated a stock repurchase plan on Monday, November 17th that authorizes the company to buyback $250.00 million in outstanding shares. This buyback authorization authorizes the company to reacquire up to 3% of its shares through open market purchases. Shares buyback plans are often a sign that the company’s management believes its shares are undervalued.

Analyst Ratings Changes

A number of research analysts have recently weighed in on HIMS shares. Barclays began coverage on Hims & Hers Health in a research report on Monday, December 8th. They set an “overweight” rating and a $48.00 price objective for the company. BTIG Research reaffirmed a “buy” rating and issued a $85.00 price objective on shares of Hims & Hers Health in a research note on Tuesday, November 4th. UBS Group set a $32.00 price objective on Hims & Hers Health in a report on Tuesday, November 4th. KeyCorp assumed coverage on shares of Hims & Hers Health in a report on Tuesday, October 21st. They issued a “sector weight” rating for the company. Finally, Bank of America boosted their price target on shares of Hims & Hers Health from $28.00 to $32.00 and gave the stock an “underperform” rating in a research report on Tuesday, November 4th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, ten have given a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat.com, Hims & Hers Health has a consensus rating of “Hold” and a consensus target price of $45.50.

Insider Transactions at Hims & Hers Health

In other news, COO Michael Chi sold 13,750 shares of the business’s stock in a transaction dated Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total value of $504,762.50. Following the completion of the sale, the chief operating officer owned 305,161 shares in the company, valued at approximately $11,202,460.31. The trade was a 4.31% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Irene Becklund sold 8,411 shares of the company’s stock in a transaction that occurred on Wednesday, December 17th. The stock was sold at an average price of $36.71, for a total transaction of $308,767.81. Following the completion of the sale, the insider directly owned 2,126 shares of the company’s stock, valued at $78,045.46. The trade was a 79.82% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 230,835 shares of company stock valued at $11,113,714 over the last three months. 13.71% of the stock is currently owned by corporate insiders.

Hims & Hers Health Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.